What's the latest with investigational drugs for soft tissue sarcoma?
Expert opinion on investigational drugs(2022)
摘要
Immune-oncology drugs (IOs) show promise in certain subtypes of STS, but it is recognized that PD-1/PD-L1 axis inhibition is not enough on its own. Better trial stratifications based on the molecular categorization of different subtypes of STS are needed, and more evidence suggests that 'one size fits all' treatment is no longer sustainable in this heterogeneous and aggressive group of tumors.
更多查看译文
关键词
STS,Soft tissue sarcoma,adoptive cell therapy,combination therapy,immunotherapy,targeted therapy,tyrosine-kinase inhibitors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要